China Grants Breakthrough Designation to Orelabrutinib-Mesutoclax Combination

Company: InnoCare Pharma · Event Type: Regulatory Designation (China) · Regimen: Orelabrutinib + Mesutoclax (BTK + BCL2 Inhibitor Combination) · Indication: Marginal Zone Lymphoma (Relapsed/Refractory) · Designation Date: August 3, 2026 Summary China’s Center for Drug Evaluation granted Breakthrough Therapy Designation to InnoCare’s all-oral orelabrutinib…